Screening Circulating Tumor Cells as a Noninvasive Cancer Test in 3388 Individuals from High-Risk Groups (ICELLATE2)

Castro, Juan; Sánchez, Luis A.; Nuñez, María Teresa; Lu, Ming; Castro, Tomas; Sharifi, Hamid R; Ericsson, Christer

doi:10.1155/2018/4653109

Cited by 21 publications

(10 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CTC can be used to monitor treatment response and to predict prognosis (11)(12)(13). CTC has been proposed as a screening tool for lung cancer in high-risk groups of people (17). Based on the reviews of CTC in BC published in 2013 and 2016, maximum CTC detection rates in early stage and metastatic BC are 55% and 54%, respectively (11,18).…”

Section: Discussionmentioning

confidence: 99%

Enhancing the Screening Efficiency of Breast Cancer by Combining Conventional Medical Imaging Examinations With Circulating Tumor Cells

et al. 2021

View full text Add to dashboard Cite

PurposeUltrasound (US) and mammogram (MMG) are the two most common breast cancer (BC) screening tools. This study aimed to assess how the combination of circulating tumor cells (CTC) with US and MMG would improve the diagnostic performance.MethodsCTC detection and imaging examinations, US and MMG, were performed in 238 treatment-naive BC patients, 217 patients with benign breast diseases (BBD), and 20 healthy females. Correlations of CTC, US and MMG with patients’ clinicopathological characteristics were evaluated. Diagnostic performances of CTC, US and MMG were estimated by the receiver operating characteristic curves.ResultsCTC, US and MMG could all distinguish BC patients from the control (p < 0.0001). Area under curve (AUC) of CTC, US and MMG are 0.855, 0.861 and 0.759, respectively. While US has the highest sensitivity of 0.79, CTC and MMG have the same specificity of 0.92. Notably, CTC has the highest accuracy of 0.83. Combination with CTC increases the AUC of US and MMG to 0.922 and 0.899, respectively. Combining MMG with CTC or US increases the sensitivity of MMG to 0.87, however “CTC + MMG” has a higher specificity of 0.85. “CTC + US” performs the best in BC diagnosis, followed by “CTC + MMG” and then “US + MMG”.ConclusionCTC can be used as a diagnostic aid for BC screening. Combination with CTC increases the diagnostic potency of conventional BC screening imaging examinations, US and MMG, in BC diagnosis, especially for MMG.

show abstract

Section: Discussionmentioning

confidence: 99%

Enhancing the Screening Efficiency of Breast Cancer by Combining Conventional Medical Imaging Examinations With Circulating Tumor Cells

et al. 2021

View full text Add to dashboard Cite

show abstract

“…CTCs are tumor cells that can be used to screen and classify high-risk tumors (40). Studies have shown that CTC counts are variable in different subtypes and stages of breast cancer, and that CTCs are more frequently observed in advanced stages compared with in early stages (41,42).…”

Section: Discussionmentioning

confidence: 99%

Clinical significance of circulating tumor cells in patients with locally advanced head and neck squamous cell carcinoma

et al. 2020

View full text Add to dashboard Cite

The present study aimed to investigate the clinical relevance of circulating tumor cells (CTCs) in patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC), particularly in patients with nasopharyngeal and hypopharyngeal squamous cell carcinoma. CTCs were isolated using negative immunomagnetic bead enrichment and were identified by fluorescence in situ hybridization. Youden's index and the receiver operating characteristic (ROC) curve were used to select the optimal CTC baseline value. χ 2 test or Fisher's test were used to determine the association between CTC counts and clinical parameters, curative effects and prognosis. The Kaplan-Meier estimator was used to analyze overall survival (OS) and progression-free survival (PFS). In the present study, 356 peripheral blood samples (178 pretreatment samples and 178 post-treatment samples) from 178 patients were examined. The results revealed that the pretreatment CTC detection rate was 73.8%. The minimum, maximum and median CTC counts were 1, 22 and 2/3.2 ml, respectively. The number of polyploid CTCs was associated with distant metastasis (P=0.026). In addition, patients with undetectable CTCs, and decreasing or negative CTCs post-treatment tended to have a good prognosis (P<0.05). For nasopharyngeal squamous cell carcinoma, the PFS of patients with increased CTCs and CTCs ≥2/3.2 ml after treatment was significantly lower (P<0.05). For hypopharyngeal squamous cell carcinoma, it was suggested that CTCs with a cutoff value of 3 may be used to evaluate PFS and OS before and after treatment. In conclusion, CTCs may be used to monitor disease progression and the response to chemoradiotherapy for patients with LA-HNSCC. Furthermore, CTCs are a better predictor of the prognosis of hypopharyngeal squamous cell carcinoma than that of nasopharyngeal squamous cell carcinoma.

show abstract

“…Castro et al have evaluated blood samples of 3388 individuals aged 45-80 years with no cancer history. They found circulating non-haematological cells in the blood of 107 (3.2%) individuals (67). In lung cancer, there were attempts to combine CTC assessment with established screening methods.…”

Section: Utilization Of Ctc In Monitoring Disease Developmentmentioning

confidence: 99%

Circulating Tumor Cells in Diagnosis and Treatment of Lung Cancer

Malý

Kološtová

et al. 2019

In Vivo

View full text Add to dashboard Cite

Circulating tumor cells (CTCs), detached from the primary tumor or metastases and shed in the patient's bloodstream, represent a relatively easily obtainable sample of the cancer tissue that can indicate the actual state of cancer, and their evaluation can be repeated many times during the course of treatment. As part of liquid biopsy, evaluation of CTCs provides a lot of clinically relevant information, which reflects the actual, real-time conditions of the disease. CTCs can be used in cancer diagnosis or screening, real-time longterm disease monitoring and even therapy guidance. Their analysis can include their number, morphology, and biological features by using immunocytochemistry and all "-omic" technologies. This review describes methods of CTC isolation and potential clinical utilization in lung cancer. Despite major advances in the diagnostics and treatment, lung cancer remains the most lethal cancer disease on a global scale. According to a WHO estimate, there were 2.09 million new lung cancer cases and 1.76 million lung cancer-related deaths in 2018 (1). Therefore, similarly to other cancer diagnoses, a significant effort is dedicated on the potential use of circulating tumor cells (CTCs) in prognosis assessment, disease monitoring and even in therapy management. CTCs, detached from the primary tumor or metastases and shed in patient's bloodstream, represent a relatively easily obtainable sample of cancer tissue. As a liquid biopsy, evaluation of CTCs provides a lot of clinically relevant information, which reflects the actual, real-time conditions of the disease (2). CTCs are very rare in the bloodstream; therefore, a number of different enrichment and isolation methods have been developed (2). Also, the evaluation of CTCs can be performed on many levels providing different kinds of information. The CTCs enrichment methods as well as their potential clinical use in lung cancer is introduced below. CTC Isolation and Detection Methods-Basic Principles Exploration of CTCs can provide a lot of clinically-relevant information; however, CTCs are very rare in the bloodstream. Every single CTC is surrounded by 10 6-10 7 mononuclear white blood cells (2, 3). Therefore, in order to be able to study and assess CTC-number and characteristics, it is necessary to separate them from the ambient blood cells. Although many methods have been developed to isolate CTCs, there are only two basic approaches to isolate CTCs: a) isolation methods based on detection of specific surface markers of the CTCs (and/or white blood cells), also called "label-dependent systems/methods" and b) methods independent of specific markers, based on physical or biological properties of the CTCs, "label-independent systems/methods" (2).

show abstract

Screening Circulating Tumor Cells as a Noninvasive Cancer Test in 3388 Individuals from High-Risk Groups (ICELLATE2)

Cited by 21 publications

References 17 publications

Enhancing the Screening Efficiency of Breast Cancer by Combining Conventional Medical Imaging Examinations With Circulating Tumor Cells

Enhancing the Screening Efficiency of Breast Cancer by Combining Conventional Medical Imaging Examinations With Circulating Tumor Cells

Clinical significance of circulating tumor cells in patients with locally advanced head and neck squamous cell carcinoma

Circulating Tumor Cells in Diagnosis and Treatment of Lung Cancer

Contact Info

Product

Resources

About